## **ICMJE DISCLOSURE FORM**

Date: AUGUST	4, 2021			
Your Name: YVETTE	TAWHEHCO			
Manuscript Title:	GRANULOCYTE	TRANSFUSION	THERAPY	
Manuscript number (i	fknown): AOB	-21-46		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	金色型 植外型 伊拉斯斯	Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
	<b>2.</b>	Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	LEUKOCYTES LLC

				1
5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
U	testimony	None		1
	testimony			
7	Support for attending	None		
	meetings and/or travel			
8	Patents planned, issued or	None		
	pending			
		,		
9	Participation on a Data	None		
	Safety Monitoring Board or	Tronc		
	Advisory Board			-
			Manks Control At Date Co	2.100
10	Leadership or fiduciary role in other board, society,	None	BBANNS- BOARD OF DIRECTOR, COMMITT	EE CHAIR
			ASFA - COMMITTEE CHAIR	
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	✓ None		
			A	
12	Possint of aguinment	None		
12	Receipt of equipment,			
	materials, drugs, medical	*		
	writing, gifts or other		그렇다 보는 게 되었다. 귀나는 이 선생님이 없었다.	
	services			
13	Other financial or non-	None		
	financial interests			
				1
		<u> </u>		

Please summarize the above conflict of interest in the following box:

I DON'T	THINK	1 HAVE	Any	RELEVANT	FINANCIAL	INTAUSTS
BUT LIST I AM OWN I AM ON	CATIONAL THE B	NSULTANT TOPICS DARD OF	DIREC	LEUKOCYT AL CASES. TORS FOR	ESLLC.1001 BBANYS + CO	USULT MOSTLY
CHAIROF	BBANY!	s & ASFA				

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.